http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-029906-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_096a1603c6abd9836906a6226c0cda78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00 |
| filingDate | 2001-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5cf00334b120a1c090fcc038a57f92b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7366d5a3a0dd47ae8545a5e9bd54013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85ccbb40c62273f7e1dd1c7912dc544b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c28c1029010c97e00b4c76e1a602abb7 |
| publicationDate | 2003-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-029906-A1 |
| titleOfInvention | PROCESS FOR OBTAINING THE ENANTIOMERS OF THE BUPIVACAINA RACEMICA, PROCESS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS BASED ON LEVOBUPIVACAINE; PHARMACEUTICAL COMPOSITIONS BASED ON LEVOBUPIVACAIN FORMULATED IN THE BASIC OR SALES PHARMACEUTICALLY ACCEPTABLE FORMS AND USE OF COMPOSI |
| abstract | A method of separating the two enantiomers of bupivacaine is described, which consists of a continuous process of separation at room temperature, via a selective precipitation of its diastereomers with tartaric acid, preferably L - (+) - tartaric acid, as a resolution agent. . The process carried out at room temperature prevents thermal degradation of the reagents allowing continuous and even automated processing. The enantiomeric manipulation of said diastereomers to obtain pharmaceutical compositions with varied enantiomeric excesses of levobupivacaine is also described, in order to determine and quantify the participation of dextrobupivacaine in the anesthetic and cardiotoxic effects of the drug. The enantiomerically manipulated compositions have anesthetic properties similar to those of racemic bupivacaine, but with a cardiotoxicity similar to that of pure levobupivacaine, that is, inferior to that of racemic bupivacaine. |
| priorityDate | 2000-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.